Ascendis Pharma Files 6-K, Incorporates by Reference
Ticker: ASND · Form: 6-K · Filed: Jul 9, 2025 · CIK: 1612042
Sentiment: neutral
Topics: regulatory-filing, sec-filing, form-6k
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K, incorporating previous S-8 filings. Nothing new, just housekeeping.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on July 9, 2025, to report information as a foreign private issuer. The filing is related to registration statements on Form S-8, specifically referencing Registration Numbers 333-203040 and 333-217754.
Why It Matters
This filing indicates ongoing regulatory reporting and potential updates related to employee stock plans or other securities offerings, which can be relevant for investors tracking corporate actions.
Risk Assessment
Risk Level: low — The filing is a routine report and does not appear to contain new material financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — Commission File Number
- 333-203040 (company) — Form S-8 Registration Number
- 333-217754 (company) — Form S-8 Registration Number
FAQ
What is the purpose of this Form 6-K filing by Ascendis Pharma A/S?
The Form 6-K is a report of a foreign private issuer filed for the month of July 2025, and it is being incorporated by reference into existing registration statements on Form S-8.
What are the specific Form S-8 registration numbers mentioned in the filing?
The filing specifically mentions Form S-8 Registration Numbers 333-203040 and 333-217754.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on July 9, 2025.
What is Ascendis Pharma A/S's principal executive office address?
Ascendis Pharma A/S's principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Does Ascendis Pharma A/S file annual reports under Form 20-F or Form 40-F?
Ascendis Pharma A/S indicates that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 9, 2025 regarding Ascendis Pharma A/S (ASND).